Multiple myeloma trials in Spain
82 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 1RecruitingTrial-stage medicine
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568EU 2023-507019-36-00Registry updated 2026-10-20
Phase 3RecruitingResearch participation
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
- Where
- Badalona, Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla
- Age
- 18 years and over
- People
- 206 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-523815-12-00EU 2025-523815-12-00Registry updated 2026-10-19
Phase 2/3RecruitingTrial-stage medicine
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Where
- Badalona, Barcelona, Las Palmas De Gran Canaria, León, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Valencia
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- AbbVie
See details and how to joinNCT07095452EU 2025-520897-21-00Registry updated 2026-10-19
Phase 2Enrolling by invitationTrial-stage medicine
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Where
- Badalona, Madrid, Pamplona, Salamanca, Santander, Seville
- Age
- 18 years and over
- People
- 70 worldwide
- Run by
- Sanofi
See details and how to joinNCT05669989Registry updated 2026-10-15
Phase 3RecruitingResearch participation
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Where
- A Coruña, Badalona, Barcelona, Cáceres, Donostia, Granada, Jerez de la Frontera, León, Lugo, Madrid, Málaga, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela, Sevilla, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 423 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-526654-14-01EU 2026-526654-14-01Registry updated 2026-10-14
Phase 3RecruitingTrial-stage medicine
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Badalona, Barcelona, Elche, Madrid, Santander
- Age
- 18 years and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264EU 2026-525626-38-00Registry updated 2026-10-14
Phase 2Not yet recruitingResearch participation
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
- Where
- Albacete, Alicante, Badalona, Barcelona, Gijón, Granada, Las Palmas De Gran Canaria, L'hospitalet De Llobregat, Lugo, Madrid, Marbella, Murcia, Oviedo, Palma, Pamplona, Salamanca, Santander, Valencia, Vitoria
- Age
- 18 years and over
- People
- 60
- Run by
- Fundacion PETHEMA
See details and how to join2026-526352-31-00EU 2026-526352-31-00Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Madrid, Marbella, Palma, Salamanca, Valencia
- Age
- 18 years and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480EU 2024-518420-80-00Registry updated 2026-10-13
Phase 3RecruitingTrial-stage medicine
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Badalona, Barcelona, Madrid, Marbella, Pamplona, Salamanca
- Age
- 18 years and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938EU 2025-524028-23-00Registry updated 2026-10-13
Phase 3Not yet recruitingResearch participation
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
- Where
- Badalona, Barcelona, Madrid, Murcia, Salamanca, Santander, Sevilla
- Age
- 18 years and over
- People
- 249 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-525367-40-00EU 2026-525367-40-00Registry updated 2026-10-12
No phaseRecruitingResearch participation
Effects of Controlled Breathing Added to Therapeutic Exercise in Multiple Myeloma
- Where
- Madrid
- Age
- 18 years and over
- People
- 32
- Run by
- Universidad Complutense de Madrid
See details and how to joinNCT07312942Registry updated 2026-10-01
No phaseRecruitingResearch participation
Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma
- Where
- Madrid
- Age
- 18 years and over
- People
- 26
- Run by
- Universidad Complutense de Madrid
See details and how to joinNCT07376733Registry updated 2026-10-01
Phase 3RecruitingTrial-stage medicine
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Where
- Badalona, Cáceres, Madrid, Pamplona, Valencia, Clinica Universidad De Navarra, Hospital Universitario Quironsalud Madrid
- Age
- 18 years and over
- People
- 49 worldwide
- Run by
- Grifols Biologicals, LLC
See details and how to joinNCT07582432EU 2026-526803-31-00Registry updated 2026-10-01
Phase 3RecruitingTrial-stage medicine
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia
- Age
- 18 years and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657Registry updated 2026-09-29
Phase 2RecruitingTrial-stage medicine
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Where
- Badalona, Barcelona, Jerez de la Frontera, Madrid, Murcia, Pozuelo de Alarcón, Salamanca
- Age
- 18 years and over
- People
- 210 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06500884EU 2023-506260-14-00Registry updated 2026-09-25
Phase 1RecruitingTrial-stage medicine
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Where
- Barcelona, Salamanca
- Age
- 18 years and over
- People
- 276 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06768489EU 2024-515316-44-00Registry updated 2026-09-25
Phase 3RecruitingTrial-stage medicine
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Barcelona, Cáceres, Córdoba, Jerez de la Frontera, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186Registry updated 2026-09-25
Phase 2Enrolling by invitationTrial-stage medicine
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
- Where
- Barcelona
- Age
- 1 year and over
- People
- 500 worldwide
- Run by
- Autolus Limited
See details and how to joinNCT03628612Registry updated 2026-09-22
Phase 1/2RecruitingTrial-stage medicine
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Where
- Barcelona, Madrid, Murcia, Palma, Sevilla
- Age
- 18 years and over
- People
- 78 worldwide
- Run by
- Heidelberg Pharma AG
See details and how to joinNCT04879043EU 2024-515273-10-00Registry updated 2026-09-17
Phase 3RecruitingResearch participation
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Where
- Barcelona
- Age
- 18 years and over
- People
- 309 worldwide
- Run by
- Lakefront Biotherapeutics
See details and how to join2023-510173-34-00EU 2023-510173-34-00Registry updated 2026-09-11
Phase 2RecruitingResearch participation
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
- Where
- Barcelona, León, Madrid, Málaga, Pamplona, Valencia
- Age
- 18 years and over
- People
- 123 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-524793-42-00EU 2025-524793-42-00Registry updated 2026-09-11
Phase 3Not yet recruitingResearch participation
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca, Sevilla, Valencia
- Age
- 18 years and over
- People
- 234 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524014-29-00EU 2025-524014-29-00Registry updated 2026-09-08
Phase 1/2RecruitingTrial-stage medicine
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Where
- Salamanca, Santander
- Age
- 18 years and over
- People
- 62 worldwide
- Run by
- Celgene
See details and how to joinNCT06988488EU 2025-522090-11-00Registry updated 2026-09-02
Phase 1Not yet recruitingResearch participation
A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
- Where
- Barcelona, Salamanca, Sevilla
- Age
- 18 years and over
- People
- 25 worldwide
- Run by
- TOLREMO therapeutics AG
See details and how to join2025-523536-39-00EU 2025-523536-39-00Registry updated 2026-08-28
No phaseRecruitingResearch participation
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
- Where
- Ávila, Granada, Madrid, Málaga, Valencia, Vigo
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Janssen-Cilag Ltd.
See details and how to joinNCT06285318Registry updated 2026-08-28
All Multiple myeloma trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.